Xenoport rallies on positive RLS data

Shares of XenoPort surged on the news that its therapy for restless leg syndrome delivered positive data in a late-stage study. Researchers for the company noted that XP13512 hit both its primary goals in demonstrating a statistically significant improvement in symptoms. More Phase III data will be released at an upcoming conference. Investors weren't waiting, though, bidding up XenoPort shares by 25 percent.

"These results are very encouraging and represent a major advance for XenoPort, its partners and, potentially, RLS patients," said Ronald W. Barrett, Ph.D., chief executive officer of XenoPort.

- check out the release on the RLS data
- read the AP report

Related Articles:
GSK sees success with RLS campaign. Report
XenoPort inks $630M licensing deal for nerve drug. Report
XenoPort touts IIb data for new RLS therapy. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.